Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LINZESS vs LINACLOTIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Linaclotide is a guanylate cyclase-C (GC-C) agonist that activates GC-C on the luminal surface of intestinal epithelial cells, increasing intracellular cyclic guanosine monophosphate (c GMP) levels. Elevated c GMP stimulates chloride and bicarbonate secretion into the intestinal lumen, increasing fluid secretion and accelerating gastrointestinal transit. Additionally, it reduces visceral pain by decreasing activity of pain-sensing nerves.
Agonist of guanylate cyclase-C (GC-C) receptor on luminal surface of intestinal epithelial cells, increasing cyclic guanosine monophosphate (c GMP) levels, which activates CFTR ion channel, increasing chloride and water secretion into intestinal lumen, accelerating colonic transit and reducing visceral pain.
Treatment of irritable bowel syndrome with constipation (IBS-C) in adults,Treatment of chronic idiopathic constipation (CIC) in adults,Off-label: Treatment of constipation-predominant IBS in pediatric patients (limited data)
Irritable bowel syndrome with constipation (IBS-C),Chronic idiopathic constipation (CIC)
72 mcg to 290 mcg orally once daily on an empty stomach at least 30 minutes before the first meal of the day.
145 mcg orally once daily, at least 30 minutes before the first meal of the day.
Terminal half-life is 6.6 hours (range 4 – 12 h) in healthy subjects; not prolonged in renal or hepatic impairment.
Approximately 9–10 hours (terminal half-life in plasma), supporting once-daily dosing.
Linaclotide is minimally absorbed systemically and is metabolized within the gastrointestinal tract to its active peptide. No significant hepatic metabolism occurs; the primary route of elimination is fecal excretion as the active peptide.
Minimally metabolized; primarily degraded by intestinal peptidases. Not a substrate for CYP450 enzymes.
Primarily fecal (95%) as intact drug; renal excretion accounts for <1%.
Primarily fecal as intact peptide (95%); renal excretion of absorbed drug is minimal (<5%).
Approximately 94% bound to human serum albumin.
Approximately 94% bound to plasma proteins (primarily albumin).
Mean Vd is 4.4 L/kg, indicating extensive extravascular distribution into tissues.
~5.2 L/kg (large Vd indicating extensive tissue distribution).
Oral bioavailability is approximately 4% due to extensive first-pass metabolism and low systemic absorption.
Oral: ~0.1% (extremely low due to extensive degradation in GI tract and first-pass metabolism).
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment or end-stage renal disease; use cautiously.
No dose adjustment required for any degree of renal impairment, including end-stage renal disease on dialysis.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not recommended in severe hepatic impairment (Child-Pugh C) due to lack of data.
No dose adjustment required for mild, moderate, or severe hepatic impairment (Child-Pugh class A, B, or C).
For functional constipation in pediatric patients: 72 mcg orally once daily for ages 6-17 years. Safety and efficacy not established below 6 years.
Not approved for use in pediatric patients; safety and efficacy not established.
No specific dose adjustment; start at 72 mcg daily. Monitor for diarrhea and electrolyte disturbances, especially in patients >65 years.
No specific dose adjustment; caution advised due to potential increased sensitivity or gastrointestinal effects, but no pharmacokinetic differences observed in elderly vs younger adults.
WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS LESS THAN 2 YEARS OF AGE. Linaclose is contraindicated in pediatric patients up to 6 years of age. In young juvenile mice, linaclotide caused deaths due to dehydration; this risk was highest in mice less than 3 weeks of age (approximately equivalent to human pediatric patients less than 2 years of age). Use LINZESS in pediatric patients from 6 to less than 18 years of age only for the treatment of functional constipation (FC) and after evaluating the risk of dehydration and ensuring adequate fluid intake.
No boxed warning.
Risk of serious dehydration in pediatric patients less than 2 years of age; contraindicated in patients up to 6 years of age.,Diarrhea: May cause severe diarrhea, especially during the first few weeks of treatment; if severe, discontinue use and rehydrate.,Do not use in patients with known or suspected mechanical gastrointestinal obstruction.
Not recommended in pediatric patients; avoid use in patients with known or suspected mechanical gastrointestinal obstruction.,May cause diarrhea, which can be severe; instruct patients to discontinue if severe diarrhea occurs.,Use caution in patients with inflammatory bowel disease (Crohn's, ulcerative colitis) or a history of colonic obstruction.
Pediatric patients up to 6 years of age (risk of serious dehydration).,Known or suspected mechanical gastrointestinal obstruction.,Hypersensitivity to linaclotide or any component of the formulation.
Known or suspected mechanical gastrointestinal obstruction.,History of a serious hypersensitivity reaction to linaclotide or any component of the formulation.
Take on an empty stomach; avoid taking with food as food reduces absorption and efficacy.
Food reduces the efficacy of linaclotide; administer at least 30 minutes before a meal. Avoid taking with high-fat meals as they may delay gastric emptying and reduce drug effect. No specific dietary restrictions but maintaining adequate hydration is recommended due to possible diarrhea.
Linzess (linaclotide) is a guanylate cyclase-C agonist. Animal studies (rats, rabbits) at doses up to 800 mcg/kg/day showed no evidence of teratogenicity. There are no adequate and well-controlled studies in pregnant women. Based on animal data, the risk of major birth defects is low, but due to lack of human data, use only if clearly needed. First trimester: No known specific risk. Second and third trimesters: No known specific risk. No placental transfer data available; linaclotide is a large peptide with minimal systemic absorption, likely negligible fetal exposure.
Linaclotide is not systemically absorbed after oral administration; animal studies at high oral doses showed no teratogenicity. No human data available; risk to fetus is likely low due to negligible systemic exposure.
No human data on linaclotide excretion in breast milk. Animal studies show low levels in rat milk with M/P ratio approximately 0.1-0.2. Due to minimal systemic absorption after oral administration, excretion into human milk is expected to be negligible. However, caution is advised. No adverse effects observed in nursing pups in animal studies. Consider benefits vs risks.
Linaclotide is minimally absorbed systemically; its active metabolite is not measurable in plasma. No data on presence in human milk. M/P ratio unknown; likely low risk due to poor oral bioavailability and large molecular size.
No pharmacokinetic data on linaclotide in pregnancy. Due to minimal systemic absorption, significant pharmacokinetic changes are unlikely. No dose adjustment recommended in pregnancy. Standard dosing for chronic idiopathic constipation or irritable bowel syndrome with constipation (145 mcg or 290 mcg once daily) may be used if clinically indicated. Use caution in third trimester if risk of dehydration due to diarrhea.
No dose adjustment needed; pharmacokinetic changes in pregnancy do not affect systemic exposure due to negligible absorption.
Initiate at 290 mcg daily for IBS-C; 145 mcg daily for CIC; take on empty stomach at least 30 minutes before first meal; capsules must be swallowed whole; clinical response may take 2-4 weeks; contraindicated in patients with known or suspected mechanical GI obstruction; avoid in pediatric patients less than 2 years of age due to risk of serious diarrhea and dehydration.
Linaclotide is a guanylate cyclase-C agonist approved for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Onset of action can occur within 24 hours but maximal effect may take 1-2 weeks. Contraindicated in pediatric patients under 6 years due to risk of severe diarrhea. Avoid use in patients with mechanical gastrointestinal obstruction. Monitor for diarrhea, which may require dose reduction or discontinuation. Capsules should be swallowed whole; do not crush or chew. For patients with difficulty swallowing, capsules may be opened and sprinkled on applesauce or mixed in water for immediate consumption. Renal or hepatic impairment does not require dose adjustment. Linaclotide is not systemically absorbed (active locally).
Take LINZESS at least 30 minutes before your first meal of the day on an empty stomach.,Swallow capsules whole; do not crush, chew, or open them.,Do not take LINZESS if you have a bowel blockage (intestinal obstruction).,Common side effects include diarrhea, abdominal pain, and gas; severe diarrhea may occur, especially in children under 2 years.,Tell your doctor if you have severe or persistent diarrhea, or if you experience symptoms of dehydration.
Take linaclotide on an empty stomach, at least 30 minutes before the first meal of the day.,Swallow capsules whole; do not crush, chew, or break. If needed, open capsule and mix contents with applesauce or water and take immediately.,Do not take within 1 hour of eating or if you have a bowel obstruction.,Common side effects include diarrhea, which may be severe. Stop the medication and contact your doctor if you experience persistent or severe diarrhea.,Do not use in children under 6 years old.,Store at room temperature away from moisture and heat.,Keep out of reach of children and pets.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LINZESS vs LINACLOTIDE, answered by our medical review team.
LINZESS is a Guanylate Cyclase-C Agonist that works by Linaclotide is a guanylate cyclase-C (GC-C) agonist that activates GC-C on the luminal surface of intestinal epithelial cells, increasing intracellular cyclic guanosine monophosphate (c GMP) levels. Elevated c GMP stimulates chloride and bicarbonate secretion into the intestinal lumen, increasing fluid secretion and accelerating gastrointestinal transit. Additionally, it reduces visceral pain by decreasing activity of pain-sensing nerves.. LINACLOTIDE is a Guanylate Cyclase-C Agonist that works by Agonist of guanylate cyclase-C (GC-C) receptor on luminal surface of intestinal epithelial cells, increasing cyclic guanosine monophosphate (c GMP) levels, which activates CFTR ion channel, increasing chloride and water secretion into intestinal lumen, accelerating colonic transit and reducing visceral pain.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LINZESS and LINACLOTIDE depend on the specific clinical indication. These are both Guanylate Cyclase-C Agonist agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LINZESS is: 72 mcg to 290 mcg orally once daily on an empty stomach at least 30 minutes before the first meal of the day.. The standard adult dose of LINACLOTIDE is: 145 mcg orally once daily, at least 30 minutes before the first meal of the day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LINZESS and LINACLOTIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LINZESS is classified as Category C. Linzess (linaclotide) is a guanylate cyclase-C agonist. Animal studies (rats, rabbits) at doses up to 800 mcg/kg/day showed no evidence of teratogenicity. There are no adequate and. LINACLOTIDE is classified as Category C. Linaclotide is not systemically absorbed after oral administration; animal studies at high oral doses showed no teratogenicity. No human data available; risk to fetus is likely low. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.